The results of a study published last month in the journal Haemophilia demonstrated that a prophylactic treatment regimen for children with severe hemophilia B using a recombinant factor IX (rFIX) product may be employed safely and effectively.
On February 17, 2010, the U.S. Food and Drug Administration (FDA) warned consumers about the potential for serious side effects by mistakenly taking Maalox® Total Relief instead of other Maalox® products.
In December 2013, the US Food and Drug Administration (FDA) approved Sovaldi (sofosbuvir), a daily oral nucleotide analogue inhibitor, for the treatment of four genotypes of hepatitis C viral (HCV) infection -- 1, 2, 3 and 4.
Last month, Novo Nordisk announced that the US Food and Drug Administration (FDA) approved TRETTEN®, the first recombinant factor XIII A-subunit therapy for the routine prophylaxis of bleeding in individuals with inherited factor XIII (FXIII) A-subunit deficiency.
The American Association for the Study of Liver Diseases and the Infectious Diseases Society of America (IDSA), in collaboration with the International Antiviral Society-USA, have developed a website for the rapid dissemination of evidence-based, expert-developed recommendations for hepatitis C virus (HCV) management.
Investigators at the University of North Carolina (UNC) School of Medicine and Medical College of Wisconsin (MCW) developed a gene therapy approach that uses platelets, avoiding the kind of antibody response (inhibitors) that can neutralize an infused factor therapy.
The US Food and Drug Administration (FDA) has approved FEIBA for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A or B who have developed inhibitors.